



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

**THE ROLE OF THE INDUCIBLE TRANSCRIPTION
FACTORS IN STATUS EPILEPTICUS-INDUCED
DELAYED NEURONAL DEATH.**

**Kerin Maree Preston
(nee Singleton)**

**A thesis submitted for the degree of Doctor of Philosophy,
Faculty of Medicine, University of Auckland, 1995.**

**Department of Pharmacology and Clinical Pharmacology,
School of Medicine, University of Auckland,
New Zealand.**

ABSTRACT.

Status epilepticus (SE) is a serious neurological disorder, characterised by prolonged and/or frequent seizure activity. Following SE, a selective and delayed neuronal death (DND) occurs in limbic regions of the brain, particularly in the hippocampus. The objective of this thesis was to investigate the molecular basis of SE-induced DND in the Wistar rat hippocampus.

Following the induction of SE, moribund (i.e. dead/dying) neurons were identified by histological staining, DNA fragmentation and an increase in activated microglia. Clusterin, a glycoprotein implicated in apoptotic cell death was also observed to accumulate in the soma and axons of moribund neurons 72-144 hr following SE. Morphological evidence suggested that dying neurons exhibited many of the classical features of apoptosis (i.e. apoptotic body formation, oligo-nucleosomal DNA fragmentation and rapid phagocytosis of debris) and therefore raised the possibility that SE-induced DND might be programmed (i.e. requiring *de novo* protein synthesis).

To investigate this hypothesis I have examined the temporal and anatomical expression of a number of proteins which may have a critical role in SE-induced DND. The expression of the inducible transcription factors (ITFs) was examined as they couple extracellular stimulation to the transcription of late effector gene(s), resulting in long-term phenotypical changes in the neuron and therefore, they may couple SE-inducing stimulation with DND. A high correlation was shown between neurons which exhibited a delayed and prolonged ITFP expression and those which were selectively vulnerable to SE-induced DND (e.g. CA1 and CA3 pyramidal cells and dentate hilar neurons). However, administration of the protein synthesis inhibitor anisomycin following the induction of SE reduced the ITFPs expression, but resulted in an increase in SE-induced DND after 48 hr. However, the levels of brain-derived neurotrophic factor (BDNF)-like immunoreactivity were also shown to attenuate at this time after this procedure. Thus, protein synthesis inhibitors administered following SE may attenuate the level of trophic support and promote cell death.

To further investigate the role of the ITFPs in nerve cell death, etoposide, a DNA topoisomerase II inhibitor, which is known to facilitate apoptosis was infused into the hippocampus. The results suggested that a complex ITFP expression occurred which preceded nerve cell death. Moreover, this nerve cell death occurred earlier (12-24 hr) and was not anatomically selective. Furthermore, following the etoposide infusion, clusterin was expressed in the hippocampal pyramidal cells, in the dentate hilar neurons and in the dentate granule cells, however the latter exhibited the strongest BDNF-like immunoreactivity.

In summary, circumstantial evidence suggests that the ITFPs may form a critical component in the cascade of events which couple toxic stimulation to nerve cell death. However, this thesis demonstrates that the ITFPs have a complex role in DND, as although the ITFPs may be sufficient to induce DND, they may not always be necessary (e.g. in the absence of sufficient trophic support).

PUBLICATIONS RESULTING IN PART OR FULL FROM THIS THESIS.

Published Journal Articles

Dragunow, M., Young, D., Hughes, P., MacGibbon, G., Lawlor, P., Singleton, K., Sirimanne, E., Beilharz, E., Gluckman, P. 1993. Is c-jun involved in the nerve cell death following status epilepticus and hypoxic-ischemic brain injury? *Mol. Brain Res.* Vol 18, pg 347-352.

Hughes, P., Singleton, K., Dragunow, M. 1994. MK-801 does not attenuate immediate-early gene expression following an amygdala after discharge. *Exp. Neurol.*, Vol 128, pg 276-283.

Dragunow, M., Faull, RLM., Lawlor, P., Beilharz, EJ., Singleton, K., Walker, EB., Mee, E. 1995. *In situ* evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. *NeuroReport*, Vol 6, pg 1053-1057.

Dragunow, M., Preston, K., Dodd, J., Young, D., Lawlor, P., Christie, D. (1995) Clusterin accumulates in dying neurons following status epilepticus. *Mol. Brain Res.*, Vol 32, pg 279-290.

Dragunow, M., Preston, K. (1995). The role of inducible transcription factors in apoptotic nerve cell death. *Brain Res. Rev.*, Vol 21, pg 1-28.

Published Abstracts

Singleton, K., Young, D., Dragunow, M. (1993). Cell death and immediate early genes after status epilepticus. *International Journal of Neuroscience* (abstracts for the Eleventh Australasian Winter Conference on Brain Research).

Singleton, K., Young, D., Dragunow, M. (1994). Immediate early genes expression may mediate delayed neuronal death after status epilepticus in the Wistar rat. *Soc. for Neurosci. Abs.* Vol 20, pg 247.

Singleton, K., Dragunow, M. (1994). A delayed expression of inducible transcription factors precedes etoposide-induced apoptosis *in vivo*. *Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists*, Vol 1, pg 112.

ACKNOWLEDGEMENTS.

This thesis would not be complete without my acknowledgement of several people. Firstly, I would like to thank Associate Professor Michael Dragunow, under whose enthusiastic supervision this thesis was performed. Thank you for your continuing encouragement, motivation and support, which I have relied on when my own reserves were low. I would also like to thank all the members of the Neuropharmacology Laboratory, past and present. I am particularly indebted to Debbie Young and Trish Lawlor who have provided excellent technical support both in the laboratory and in the surgery. I would also like to thank Debbie for imparting her expertise on immunoblotting to me. Finally, I would like to thank Debbie for keeping me in line when travelling to the 11th Australasian Winter Conference on Brain Research in Queenstown, New Zealand and the 24th Annual Society for Neuroscience Conference in Miami, USA. Thanks to all the students in the lab, whose friendship over the years has made the lab an enjoyable place to work: Niki Butterworth, Bronwen Connor, Michelle Glass, Paul Hughes, Geraldine MacGibbon, Chris Tse and Marshall Walton. I would like to acknowledge the assistance of the departmental secretaries Julie McGrath and Karen Donovan who were always willing to lend a hand or an opinion. I would also like to say thank you to Jon Montellone who restrained me when I wanted to throw the computer from the window.

Without the photographic expertise of Mark Shelley (Department of Anatomy) this thesis would not contain such "beautiful" photographs. Thank you Mark for spending several days in the dark room on my account. I would also like to thank Erica Beilharz (Department of Paediatrics, Research Centre for Development Medicine and Biology) for her technical advice and assistance with the isolation, extraction and electrophoresis of DNA.

This acknowledgement would not be complete with out thanking my wonderful husband Sean, whose love, support and belief in my abilities I have relied on. I would also like to thank my parents, Isobel and Wayne Singleton, whose financial and emotional support with the help of the regular Wednesday night roast chicken dinners has allowed me to

complete my thesis. To my sister Nicki, thank you for attempting to impart your photographic expertise on me, although I'm sure it has something to do with the way you hold your tongue.

I am especially grateful to the New Zealand Neurological Foundation who awarded me a WB Miller Scholarship, which allowed me to become financially independent. Finally, I would like to thank the New Zealand Neurological Foundation, the Royal Society, the Department of Pharmacology and Clinical Pharmacology, the University of Auckland Graduate Research Fund and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) for funding to attend conferences both nationally and internationally.

TABLE OF CONTENTS

ABSTRACT.	ii
PUBLICATIONS RESULTING IN PART OR FULL FROM THIS THESIS.	iv
ACKNOWLEDGEMENTS.	v
LIST OF FIGURES.	xii
LIST OF TABLES	xix
ABBREVIATIONS.	xx
 CHAPTER 1: GENERAL INTRODUCTION	 1
1.1 Status epilepticus - A model of delayed hippocampal nerve cell death.	1
1.1.1 The Etiology of SE	2
1.1.2 The neuropathology of status epilepticus	4
1.1.3 Mechanisms of SE.	6
1.2 Inducible Transcription Factors	13
1.3 Programmed Cell Death and Apoptosis	14
1.3.1 Excitotoxicity and Programmed Cell Death	16
1.3.2 Effect of RNA and/or protein synthesis inhibitors on nerve cell death	19
1.3.3 Apoptosis Activator and Repressor Genes - A Complex Homeostasis	21
1.3.4 Relevance of <i>in vitro</i> studies to the <i>in vivo</i> situation	29
1.3.5 Expression of ITF's in dying neurons	30
1.3.6 Transduction pathways inducing ITF genes in dying neurons ..	33
1.4 Aims Of This Thesis.	39
 CHAPTER 2: GENERAL METHODS	 41
2.1 Surgical Techniques	41
2.1.1 Hippocampal electrode implantation	41
2.1.2 Hippocampal and ventricular cannulation	41
2.2 Drug administration	42
2.2.1 Intra-peritoneal (i.p.) Route	42
2.2.2 Intra-cerebroventricular (i.c.v.) Route	42
2.2.3 Intra-hippocampal Route	42

2.3	Tissue processing	43
2.3.1	<i>In-Situ</i> Hybridisation	43
2.3.2	Immunocytochemistry	44
2.3.3	Immuno-Blots	46
2.3.4	Histological Staining	46
2.3.5	Isolectin B-4	47
2.3.6	<i>In Situ</i> Nick End Labelling Of DNA	47
2.3.7	DNA Isolation and Electrophoresis on an Agarose Gel	48
2.4	Analyses	49

CHAPTER 3: CHARACTERISATION OF STATUS EPILEPTICUS IN THE WISTAR

RAT.		52
3.1	Introduction	52
3.2	Methods	54
3.2.1	Treatment of sham control animals	54
3.2.2	Treatment of animals which received CHS-induced SE	54
3.2.3	Treatment of animals receiving MK-801 & kainic acid	55
3.2.4	Treatment of animals receiving MK-801 & pilocarpine	55
3.3	Results	56
3.3.1	Hippocampal After Discharge	56
3.3.2	CHS-induced SE	56
3.3.3	MK-801 & kainic acid-induced SE	57
3.3.4	MK-801 & pilocarpine-induced SE	57
3.4	Discussion	68

CHAPTER 4: HIPPOCAMPAL NERVE CELL VIABILITY AFTER STATUS

EPILEPTICUS.		70
4.1	Introduction	70
4.2	Methods	72
4.3	Results	73
4.3.1	Histological Stains	73
4.3.2	Microgliosis	74
4.3.3	DNA Fragmentation	74
4.4	Discussion	88

CHAPTER 5: CHARACTERISATION OF THE INDUCIBLE TRANSCRIPTION

FACTORS IN THE HIPPOCAMPUS FOLLOWING STATUS EPILEPTICUS. . . .	93
5.1 Introduction	93
5.2 Methods	94
5.3 Results	95
5.3.1 ITF mRNA and protein expression in sham control animals . . .	95
5.3.2 ITF mRNA and protein expression after CHS-induced SE	95
5.3.3 ITF mRNA and protein expression after MK-801 & kainic acid- induced SE	98
5.3.4 ITF mRNA and protein expression after MK-801 & pilocarpine- induced SE	99
5.4 Discussion	128

CHAPTER 6: THE EFFECT OF PROTEIN SYNTHESIS INHIBITION ON THE
INDUCIBLE TRANSCRIPTION FACTOR EXPRESSION AND NERVE CELL
DEATH FOLLOWING STATUS EPILEPTICUS.

	133
6.1 Introduction	133
6.2 Methods	134
6.2.1 CHS-induced SE and CHX	134
6.2.2 CHS-induced SE and ANI	135
6.2.3 Tissue Processing	136
6.3 Results	137
6.3.1 CHS and CHX	137
6.3.2 CHS and ANI	138
6.4 Discussion.	155

CHAPTER 7: INDUCIBLE TRANSCRIPTION FACTOR EXPRESSION AND
HIPPOCAMPAL NERVE CELL DEATH FOLLOWING ETOPOSIDE
INFUSION

	160
7.1 Introduction	160
7.2 Methods	162
7.2.1 Bilateral Infusions of Etoposide/Vehicle.	162
7.2.2 Unilateral infusions of CHX/vehicle (lateral ventricle) and etoposide (hippocampus)	164
7.2.3 Tissue Processing	166

7.3	Results	167
7.3.1	Bilateral hippocampal infusions of etoposide/vehicle	167
7.3.2	Unilateral infusions of CHX/vehicle (lateral ventricle) and etoposide (hippocampus)	171
7.4	Discussion	193

CHAPTER 8: THE ROLE OF CLUSTERIN IN STATUS EPILEPTICUS-INDUCED

	HIPPOCAMPAL NERVE CELL DEATH	197
8.1	Introduction	197
8.2	Methods	199
8.3	Results	200
8.4	Discussion.	213

CHAPTER 9: THE ROLE OF BRAIN-DERIVED NEUROTROPHIC FACTOR

	FOLLOWING STATUS EPILEPTICUS-INDUCED NERVE CELL DEATH	216
9.1	Introduction	216
9.2	Methods	218
9.3	Results	219
9.4	Discussion	226

CHAPTER 10: GENERAL DISCUSSION. 231

APPENDIX I: ITF NOMENCLATURE.	235
APPENDIX II: PILOT STUDIES - CHS AND ANI	236
APPENDIX III: PILOT STUDIES - ANTISENSE OLIGODEOXYNUCLEOTIDE.	242
APPENDIX IV: GENERAL MATERIALS.	246
APPENDIX V: ETHICAL APPROVAL	252
APPENDIX VI: EXPERIMENTAL DATA	253
REFERENCES	297

LIST OF FIGURES.

Figure 1.1	The proposed role of the ITFs in stimulation-transcription coupling . . .	37
Figure 1.2	Cell cycle regulated genes	38
Figure 2.1	A coronal hippocampal section showing the approximate areas from which cell counts and density measurements were performed.	51
Figure 3.1	Hippocampal after discharge	59
Figure 3.2	EEG recording before and after 1 hr of CHS	61
Figure 3.3	Scattergraph showing the onset of seizure activity following MK-801 & kainic acid	63
Figure 3.4	EEG recording before and after the administration of MK-801 (1 mg/kg, i.p.) & kainic acid (10 mg/kg, i.p.)	64
Figure 3.5	EEG recording before and after administration of MK-801 (5 mg/kg, i.p.) & kainic acid (10 mg/kg, i.p.)	65
Figure 3.6	Scattergraph showing the onset of seizure activity following MK-801 & pilocarpine	66
Figure 3.7	EEG recording before and after administration of MK-801 & pilocarpine	67
Figure 4.1	Cell viability following CHS-induced SE, as detected by cresyl violet, acid fuchsin and IB4 staining	76
Figure 4.2	High power magnification of cell viability following CHS-induced SE, as detected by cresyl violet, acid fuchsin and IB4 staining	77
Figure 4.3	The temporal and anatomical distribution of acid fuchsin staining following CHS-induced SE	78
Figure 4.4	The temporal and anatomical distribution of cresyl violet staining following CHS-induced SE	79
Figure 4.5	The temporal and anatomical distribution of IB4 staining following CHS-induced SE	80
Figure 4.6	Cell viability following MK-801 & kainic acid-induced SE, as detected by acid fuchsin, cresyl violet and IB4 staining and <i>in situ</i> nick end labelling of DNA (TUNEL)	81

Figure 4.7	The anatomical and temporal distribution of acid fuchsin staining following MK-801 & kainic acid-induced SE	82
Figure 4.8	The anatomical distribution of cresyl violet staining following MK-801 & kainic acid-induced SE	83
Figure 4.9	The anatomical distribution of activated IB4 staining following MK-801 & kainic acid-induced SE	84
Figure 4.10	<i>In situ</i> end labelling of DNA (TUNEL) in sham control animals and CHS-induced SE animals	85
Figure 4.11	Electrophoresis of DNA isolated from a sham control animal and a CHS-induced SE animal	86
Figure 4.12	<i>In situ</i> end labelling of fragmented DNA (TUNEL) in sham control animals and 6 days following SE	87
Figure 5.1	Immunoblots showing PCO6 immunoreactivity 24 hr after CHS-induced SE	100
Figure 5.2	The temporal and anatomical distribution of ITF mRNA expression following CHS-induced SE	101
Figure 5.3	The temporal and anatomical distribution of c fos mRNA expression following CHS-induced SE	102
Figure 5.4	The temporal and anatomical distribution of c jun mRNA expression following CHS-induced SE	103
Figure 5.5	The temporal and anatomical distribution of jun B mRNA expression following CHS-induced SE	104
Figure 5.6	The temporal and anatomical distribution of zif 268 mRNA expression following CHS-induced SE	105
Figure 5.7	The temporal and anatomical distribution of C FOS, C JUN and JUN B- like immunoreactivity following CHS-induced SE	106
Figure 5.8	The temporal and anatomical distribution of KROX 20 and KROX 24-like immunoreactivity following CHS-induced SE	107
Figure 5.9	The temporal and anatomical distribution of C FOS-like immunoreactivity following CHS-induced SE	108
Figure 5.10	The temporal and anatomical distribution of C JUN (PCO6)-like immunoreactivity following CHS-induced SE	109

Figure 5.11	The temporal and anatomical distribution of C JUN (636/7)-like immunoreactivity following CHS-induced SE	110
Figure 5.12	The temporal and anatomical distribution of JUN B-like immunoreactivity following CHS-induced SE	111
Figure 5.13	The temporal and anatomical distribution of JUN D-like immunoreactivity following CHS-induced SE	112
Figure 5.14	The temporal and anatomical distribution of KROX 24-like immunoreactivity following CHS-induced SE	113
Figure 5.15	The temporal and anatomical distribution of KROX 20-like immunoreactivity following CHS-induced SE	114
Figure 5.16	The temporal and anatomical distribution of ITF mRNA expression following MK-801 & kainic acid-induced SE	115
Figure 5.17	The temporal and anatomical distribution of c fos mRNA expression following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	116
Figure 5.18	The temporal and anatomical distribution of c jun mRNA expression following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	117
Figure 5.19	The temporal and anatomical distribution of zif 268 mRNA expression following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	118
Figure 5.20	The temporal and anatomical distribution of jun B mRNA expression following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	119
Figure 5.21	The temporal and anatomical distribution of C FOS, C JUN and KROX 24-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE.	120
Figure 5.22	The temporal and anatomical distribution of C FOS-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	121
Figure 5.23	The temporal and anatomical distribution of C JUN-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	122
Figure 5.24	The temporal and anatomical distribution of JUN B-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	123

Figure 5.25	The temporal and anatomical distribution of JUN D-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	124
Figure 5.26	The temporal and anatomical distribution of KROX 24-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	125
Figure 5.27	The temporal and anatomical distribution of KROX 20-like immunoreactivity following MK-801 (1 or 5 mg/kg) & kainic acid-induced SE	126
Figure 5.28	The temporal and anatomical distribution of ITFP-like immunoreactivity following MK-801 & pilocarpine-induced SE	127
Figure 6.1	Photomicrographs showing the temporal and anatomical distribution of ITF mRNA expression following CHS/ANI(L), CHS/VEH(L) and ANI(L)	141
Figure 6.2	The temporal and anatomical distribution of c fos mRNA expression following CHS/ANI(L), CHS/VEH(L) and ANI(L)	142
Figure 6.3	The temporal and anatomical distribution of c jun mRNA expression following CHS/ANI(L), CHS/VEH(L) and ANI(L)	143
Figure 6.4	The temporal and anatomical distribution of zif 268 mRNA expression following CHS/ANI(L), CHS/VEH(L) and ANI(L)	144
Figure 6.5	Photographs showing the temporal and anatomical distribution of C FOS, C JUN, KROX 24 and JUN B-like immunoreactivity following CHS/ANI(L), CHS/VEH(L) and ANI(L)	145
Figure 6.6	The temporal and anatomical distribution of C FOS-like immunoreactivity following CHS/ANI(L), CHS/VEH(L) and ANI(L)	146
Figure 6.7	The temporal and anatomical distribution of C JUN-like immunoreactivity following CHS/ANI(L), CHS/VEH(L) and ANI(L)	147
Figure 6.8	The temporal and anatomical distribution of KROX 24-like immunoreactivity following CHS/ANI(L), CHS/VEH(L) and ANI(L)	148
Figure 6.9	The temporal and anatomical distribution of JUN B-like immunoreactivity following CHS/ANI(L), CHS/VEH(L) and ANI(L)	149
Figure 6.10	Cell viability following CHS/ANI(L) and CHS/VEH(L)	150
Figure 6.11	The temporal and anatomical distribution of cresyl violet staining following CHS/ANI(L), CHS/VEH(L) and ANI(L)	151

Figure 6.12	The temporal and anatomical distribution of acid fuchsin staining following CHS/ANI(L), CHS/VEH(L) and ANI(L)	152
Figure 6.13	The temporal and anatomical distribution of IB4 staining 24 and 48 hr following CHS/ANI(L), CHS/VEH(L) and ANI(L)	153
Figure 6.14	The temporal and anatomical distribution of TUNEL(+) neurons following CHS/ANI(L), CHS/VEH(L) and ANI(L)	154
Figure 7.1	Location of hippocampal etoposide and DMSO infusions	163
Figure 7.2	Anatomical location of CHX/vehicle and etoposide infusions	165
Figure 7.3	Photomicrographs showing the temporal and anatomical distribution of c fos mRNA expression following etoposide/vehicle hippocampal infusions	173
Figure 7.4	Photomicrographs showing the temporal and anatomical distribution of c jun mRNA expression following etoposide/vehicle hippocampal infusions	174
Figure 7.5	Photomicrographs showing the temporal and anatomical distribution of zif 268 mRNA expression following etoposide/vehicle hippocampal infusions	175
Figure 7.6	The temporal and anatomical distribution of c fos mRNA expression following bilateral etoposide/vehicle hippocampal infusions	176
Figure 7.7	The temporal and anatomical distribution of c jun mRNA expression following bilateral etoposide/vehicle hippocampal infusions	177
Figure 7.8	The temporal and anatomical distribution of zif 268 mRNA expression following bilateral etoposide/vehicle hippocampal infusions	178
Figure 7.9	The temporal and anatomical distribution of C FOS-like immunoreactivity following etoposide/vehicle hippocampal infusions	179
Figure 7.10	The temporal and anatomical distribution of C JUN-like immunoreactivity following etoposide/vehicle hippocampal infusions	180
Figure 7.11	The temporal and anatomical distribution of KROX 24-like immunoreactivity following etoposide/vehicle hippocampal infusions	181

Figure 7.12	The temporal and anatomical distribution of C FOS-like immunoreactivity following bilateral etoposide/vehicle hippocampal infusions	182
Figure 7.13	The temporal and anatomical distribution of C JUN-like immunoreactivity following bilateral etoposide/vehicle hippocampal infusions	183
Figure 7.14	The temporal and anatomical distribution of KROX 24-like immunoreactivity following bilateral etoposide/vehicle hippocampal infusions	184
Figure 7.15	The temporal and anatomical distribution of JUN B-like immunoreactivity following bilateral etoposide/vehicle hippocampal infusions	185
Figure 7.16	The temporal and anatomical distribution of cresyl violet staining following bilateral etoposide/vehicle hippocampal infusions	186
Figure 7.17	The temporal and anatomical distribution of acid fuchsin staining following bilateral etoposide/vehicle hippocampal infusions	187
Figure 7.18	The temporal and anatomical distribution of proliferating microglia following bilateral etoposide/vehicle hippocampal infusions	188
Figure 7.19	The temporal and anatomical distribution of TUNEL(+) neurons following bilateral etoposide/vehicle hippocampal infusions	189
Figure 7.20	The anatomical distribution of cresyl violet staining 72 hr following bilateral etoposide and vehicle hippocampal infusions	190
Figure 7.21	Photomicrographs showing the temporal and anatomical distribution of ITF mRNA expression following CHX and etoposide infusions	191
Figure 7.22	The expression of ITFP-like immunoreactivity following unilateral infusions of CHX (lateral ventricle) and etoposide (hippocampus)	192
Figure 8.1	Cell viability in the hippocampus 6 days after CHS	203
Figure 8.2	Clusterin-like immunoreactivity and clusterin mRNA expression in sham control and CHS	204
Figure 8.3	The temporal and anatomical distribution of clusterin-like immunoreactivity following CHS-induced SE	205
Figure 8.4	The temporal and anatomical distribution of clusterin-like immunoreactivity following CHS/ANI(L), CHS/VEH(L) and ANI(L)	206

Figure 8.5	Clusterin-like immunoreactivity and clusterin mRNA expression in sham control and following MK-801 (1 and 5 mg/kg, i.p.) and kainic acid-induced SE.	207
Figure 8.6	The anatomical distribution of clusterin-like immunoreactivity following MK-801 & kainic acid-induced SE	208
Figure 8.7	The temporal and anatomical distribution of nerve cell viability following etoposide/vehicle hippocampal infusions	209
Figure 8.8	The distribution of clusterin-like immunoreactivity following bilateral etoposide/vehicle hippocampal infusions	210
Figure 8.9	Photomicrographs showing FP-1 and FP-2 antisera specificity control studies on a brain 6 days after SE	211
Figure 8.10	Immunoblots showing FP 1 and FP 2-like immunoreactivity 24 hr after CHS-induced SE	212
Figure 9.1	Photographs showing BDNF-like immunoreactivity following CHS-induced SE	221
Figure 9.2	Photographs showing BDNF-like immunoreactivity 24 and 48 hr following CHS/ANI(L)	222
Figure 9.3	Photographs showing BDNF-like immunoreactivity following CHS/VEH(L) and ANI(L)	223
Figure 9.4	Photographs showing BDNF-like immunoreactivity following MK-801 (1 & 5 mg/kg, i.p.) & kainic acid (10 mg/kg,i.p.) induced-SE	224
Figure 9.5	Photographs showing BDNF-like immunoreactivity following MK-801 (7.5 mg/kg, i.p.) & pilocarpine-induced SE	225
Figure II.1	The temporal and anatomical distribution of C FOS-like immunoreactivity 24 hr following CHS/ANI(L) and CHS/ANI(R)	238
Figure II.2	The temporal and anatomical distribution of C JUN-like immunoreactivity 24 hr following CHS/ANI(L) and CHS/ANI(R)	239
Figure II.3	The temporal and anatomical distribution of KROX 24-like immunoreactivity 24 hr following CHS/ANI(L) and CHS/ANI(R)	240
Figure II.4	The temporal and anatomical distribution of JUN B-like immunoreactivity 24 hr following CHS/ANI(L) and CHS/ANI(R)	241

LIST OF TABLES.

Table 3.1	Distribution of animals which developed generalised/partial SE after CHS	60
Table 3.2	MK-801 & kainic acid-induced-SE: distribution of treatment and animals with electrode implants	62
Table 6.1	Schedule of post-stimulation CHX treatments	134
Table 6.2	Schedule of post-stimulation ANI treatments	136
Table 7.1	The numbers of animals which received an etoposide infusion into the left/right hippocampus and their post-infusion recovery time.	162
Table 7.2	The numbers of animals which received infusions of CHX/vehicle (lateral ventricle) prior to etoposide (hippocampus) and their post-infusion recovery period	164

ABBREVIATIONS.

$^{35}\text{SdATP}$	^{35}S -deoxyadenosine 5'-[α -thio]triphosphate
AED	anti-epileptic drug
AHS	Ammon's horn sclerosis
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
ANI	anisomycin (2-[p-methoxybenzyl]-3,4-pyrrolidinediol 3-acetate)
ANOVA	analysis of variance
AP	anterior posterior
AP-1	activator protein-1
ATP	adenosine triphosphate
β -AP	β -amyloid protein
β -APP	β -amyloid precursor protein
BDNF	brain-derived neurotrophic factor
bFGF	basic fibroblast growth factor
bp	base-pair
BSA	bovine serum albumin
CA1-3	Cornu Ammonis 1-3
Ca^{2+}	calcium ion
CaBP	calcium binding proteins
cAMP	cyclic adenosine monophosphate
Cdk	cyclin dependent kinases
cDNA	complementary DNA
CHS	continuous hippocampal stimulation
CHS/ANI	continuous hippocampal stimulation followed by an anisomycin infusion (icv)
CHS/VEH	continuous hippocampal stimulation followed by a vehicle infusion (icv)
CHX	cycloheximide
CNS	central nervous system
DAB	3,3'-diaminobenzidine.4 hydrochloric acid
DAG	1,2-diacylglycerol

dH ₂ O	distilled water
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
DND	delayed neuronal death
DPM	disintegrations per minute
DTT	dithiothreitol
EDTA	ethylene diaminetetra acetate
EEG	electroencephalograph
FP-1	fusion protein-1
FP-2	fusion protein-2
G0, G1, G2	gap 0, 1, 2 phase (of cell cycle)
GABA	γ -aminobutyric acid
GAP 43	growth associated protein-43
H ₂ O ₂	hydrogen peroxide
HI	hypoxic-ischemia
hr	hour
HSP	heat-shock protein
IB4	isolectin-B4
ICE	interleukin-1 β -converting enzyme
i.c.v.	intracerebroventricular
IGF	insulin-like growth factors
Ins(1,4,5)P ₃	inositol-1,4,5-triphosphate
ITF	inducible transcription factor
ITFP	inducible transcription factor protein
ip	intraperitoneal
kb	kilobase
kg	kilograms
L	lateral
LEG	late effector gene
LEGP	late effector gene protein
mL	milli-litres
M	mitosis phase (of cell cycle)
MAP kinase	mitogen-activated protein kinase

min	minute
MK-801	dizocilpine maleate or (+)-5-methyl-10,11-dihydro-5 <i>H</i> -di-benzo[<i>a,d</i>]cycloheptene-5,1-imine maleate
mRNA	messenger ribonucleic acid
NGF	nerve growth factor
NMDA	<i>N</i> -methyl- <i>D</i> -aspartate
NT	neurotrophin
PB	phosphate buffer
PBS	phosphate buffered saline
PC12	pheochromocytoma cell line
PCD	programmed cell death
PCP	phencyclidine
PFA	paraformaldehyde
PKA	protein kinase A
PKC	protein kinase C
PMSF	phenylmethylsulfonyl fluoride
PNS	peripheral nervous system
Rb	retinoblastoma gene
RNAase	ribonuclease
S	DNA synthesis phase (of cell cycle)
SAPK	stress activated protein kinase
SE	status epilepticus
SGP-2	sulphated glycoprotein-2
SOD	super oxide dismutase
SSC	standard saline-citrate
TAE	tris-acetate/EDTA buffer
TBS	tris buffered saline
TBST	tris buffered saline containing 0.05% (v/v) Tween-20
TdT	terminal deoxynucleotidyl transferase
TGF	transforming growth factor
TLE	temporal lobe epilepsy
TNF	tumour necrosis factor
trk	tyrosine-kinase-linked neurotrophic receptor

TUNEL(+)	TdT-mediated dUTP-biotin nick end labelling positive staining
V	ventral
v/v	volume/volume
VSCC	voltage-sensitive calcium channel
w/v	weight/volume